Quote | Super Quote
Future News

07/10/2026 15:44

AI Pharma trio battered by Northbound funds before resumption, Insilico Intelligence down 11%, XtalPi slides 13%

  {EconNews}7 - The AI pharma trio continues to decline, Insilico Intelligence (03696) down 10.6%, at HK$53; XtalPi Holdings (02228) down 12.9%, at HK$7.235; MegaFusion-P (07666) narrowed losses slightly, down 4.8%, at HK$16.85.

  Northbound funds resume trading tomorrow. Yesterday, biotech stocks surged, driving the biotech index higher, reaching a recent high of 16,775 points, a premium compared to pre-National Day Golden Week levels. Today, biotech stocks saw significant declines, with the biotech index currently down 2.7% at 16,309.

  Additionally, GenScript (01548), which also has AI pharma exposure, is down 13.2% and has broken below its 10-day moving average, trading at HK$42.64. Previously, GenScript's rally was fueled by the announcement that a scientific advisor from its affiliated company, Motic Medical Technology (Shanghai), won a Nobel Prize, pushing its share price to a record high of HK$49.46 yesterday.

  Currently, the Hang Seng Index stands at 24,149, down 131 points or 0.5%, with main board turnover exceeding HK$78.3 billion. The Hang Seng China Enterprises Index is at 8,085, down 43 points or 0.5%. The Hang Seng Tech Index is at 4,192, down 31 points or 0.7%. (am)
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.